DK4090363T3 - FimH-mutant, sammensætninger dermed og anvendelse deraf - Google Patents

FimH-mutant, sammensætninger dermed og anvendelse deraf Download PDF

Info

Publication number
DK4090363T3
DK4090363T3 DK21700027.2T DK21700027T DK4090363T3 DK 4090363 T3 DK4090363 T3 DK 4090363T3 DK 21700027 T DK21700027 T DK 21700027T DK 4090363 T3 DK4090363 T3 DK 4090363T3
Authority
DK
Denmark
Prior art keywords
compositions therewith
fimh
mutant
fimh mutant
therewith
Prior art date
Application number
DK21700027.2T
Other languages
Danish (da)
English (en)
Inventor
Jan Grijpstra
Eveline Marleen Weerdenburg
Jeroen Geurtsen
Kellen Cristhina Fae
Louris Jakob Feitsma
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Application granted granted Critical
Publication of DK4090363T3 publication Critical patent/DK4090363T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK21700027.2T 2020-01-16 2021-01-14 FimH-mutant, sammensætninger dermed og anvendelse deraf DK4090363T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20152217 2020-01-16
PCT/EP2021/050707 WO2021144369A1 (en) 2020-01-16 2021-01-14 Fimh mutant, compositions therewith and use thereof

Publications (1)

Publication Number Publication Date
DK4090363T3 true DK4090363T3 (da) 2024-09-30

Family

ID=69174406

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21700027.2T DK4090363T3 (da) 2020-01-16 2021-01-14 FimH-mutant, sammensætninger dermed og anvendelse deraf

Country Status (25)

Country Link
US (3) US11421003B2 (enExample)
EP (2) EP4090363B1 (enExample)
JP (2) JP7485771B2 (enExample)
KR (1) KR20220128372A (enExample)
CN (1) CN115038461A (enExample)
AR (1) AR121066A1 (enExample)
AU (1) AU2021208493B2 (enExample)
BR (1) BR112022013720A2 (enExample)
CA (1) CA3168108A1 (enExample)
DK (1) DK4090363T3 (enExample)
ES (1) ES2987890T3 (enExample)
FI (1) FI4090363T3 (enExample)
HR (1) HRP20241370T1 (enExample)
HU (1) HUE068985T2 (enExample)
IL (1) IL294445B2 (enExample)
LT (1) LT4090363T (enExample)
MX (1) MX2022008830A (enExample)
MY (1) MY209568A (enExample)
PL (1) PL4090363T3 (enExample)
PT (1) PT4090363T (enExample)
RS (1) RS66031B1 (enExample)
SA (1) SA522433319B1 (enExample)
SI (1) SI4090363T1 (enExample)
TW (1) TWI868297B (enExample)
WO (1) WO2021144369A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021144369A1 (en) 2020-01-16 2021-07-22 Janssen Pharmaceuticals, Inc. Fimh mutant, compositions therewith and use thereof
CA3173729A1 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
TW202241929A (zh) 2021-01-12 2022-11-01 美商詹森藥物公司 ＦｉｍＨ突變體、其組成物及其用途
EP4448002A1 (en) * 2021-12-17 2024-10-23 Pfizer Inc. Polynucleotide compositions and uses thereof
AU2023274371A1 (en) 2022-05-25 2024-10-31 CureVac SE Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
JP7656656B2 (ja) * 2022-06-20 2025-04-03 ファイザー・インク 大腸菌ＦｉｍＨ変異体およびその使用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドａ単糖類縁体
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
CA2284586C (en) 1997-04-01 2011-02-08 Ribi Immunochem Research, Inc. Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
US6500434B1 (en) 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
CZ301212B6 (cs) 1998-10-16 2009-12-09 Smithkline Beecham Biologicals S. A. Vakcinacní prostredek
WO2001025254A2 (en) 1999-10-04 2001-04-12 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
WO2001078777A2 (en) 2000-04-13 2001-10-25 Mossman, Sally Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
JP2004502447A (ja) 2000-07-07 2004-01-29 メディミューン，インコーポレイテッド ＦｉｍＨアドへシンタンパク質および使用方法
EP1313502A4 (en) 2000-08-18 2005-10-19 Medimmune Inc ADMINISTRATIVE PROCEDURE OF FIMH PROTEIN AS A VACCINE AGAINST HARNWAY INFECTIONS
WO2002102974A2 (en) 2000-12-08 2002-12-27 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
CN101355928B (zh) 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
JP5356807B2 (ja) 2005-05-11 2013-12-04 アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ 原核細胞由来の組み換えｎ−グリコシル化タンパク質
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
HRP20181259T1 (hr) 2008-02-20 2018-10-05 Glaxosmithkline Biologicals S.A. Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica
LT2437753T (lt) 2009-06-05 2016-12-12 Infectious Disease Research Institute Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos
US11510875B2 (en) 2012-02-07 2022-11-29 Access To Advanced Health Institute Adjuvant formulations comprising TLR4 agonists and methods of using the same
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) * 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
EA035991B9 (ru) 2014-02-24 2020-10-21 Глаксосмитклайн Байолоджикалс С.А. Новый полисахарид и его применения
EP3693379A1 (en) * 2015-05-13 2020-08-12 University of Washington Compositions and methods for treatment and prevention of uropathogenice. coli
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
TW201946650A (zh) 2018-03-12 2019-12-16 美商詹森藥物公司 針對腹內感染之疫苗
EP4077372A1 (en) 2019-12-20 2022-10-26 Vib Vzw Nanobody exchange chromatography
WO2021144369A1 (en) 2020-01-16 2021-07-22 Janssen Pharmaceuticals, Inc. Fimh mutant, compositions therewith and use thereof
TW202241929A (zh) 2021-01-12 2022-11-01 美商詹森藥物公司 ＦｉｍＨ突變體、其組成物及其用途

Also Published As

Publication number Publication date
AU2021208493A1 (en) 2022-06-30
JP2024045126A (ja) 2024-04-02
US12012435B2 (en) 2024-06-18
LT4090363T (lt) 2024-09-25
CN115038461A (zh) 2022-09-09
TW202140521A (zh) 2021-11-01
EP4461744A2 (en) 2024-11-13
US20230049056A1 (en) 2023-02-16
KR20220128372A (ko) 2022-09-20
AR121066A1 (es) 2022-04-13
SI4090363T1 (sl) 2024-10-30
JP7485771B2 (ja) 2024-05-16
HRP20241370T1 (hr) 2024-12-20
HUE068985T2 (hu) 2025-02-28
PT4090363T (pt) 2024-09-19
TWI868297B (zh) 2025-01-01
ES2987890T3 (es) 2024-11-18
SA522433319B1 (ar) 2024-07-10
US11421003B2 (en) 2022-08-23
RS66031B1 (sr) 2024-11-29
MX2022008830A (es) 2022-10-07
AU2021208493B2 (en) 2023-03-30
JP2023500749A (ja) 2023-01-10
EP4090363B1 (en) 2024-09-04
IL294445B2 (en) 2023-10-01
US20240294582A1 (en) 2024-09-05
IL294445A (en) 2022-09-01
FI4090363T3 (fi) 2024-09-25
IL294445B1 (en) 2023-06-01
MY209568A (en) 2025-07-22
US20210221856A1 (en) 2021-07-22
US12428449B2 (en) 2025-09-30
BR112022013720A2 (pt) 2022-10-11
PL4090363T3 (pl) 2024-11-25
WO2021144369A1 (en) 2021-07-22
CA3168108A1 (en) 2021-07-22
EP4461744A3 (en) 2025-01-08
EP4090363A1 (en) 2022-11-23

Similar Documents

Publication Publication Date Title
DK4090363T3 (da) FimH-mutant, sammensætninger dermed og anvendelse deraf
DK3946464T3 (da) Forbindelser og konjugater deraf
DK3719128T3 (da) Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf
DK4161935T3 (da) Brm-målrettende forbindelser og tilhørende anvendelsesmetoder
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
JP1712403S (ja) ひじ掛け椅子
DK3833682T3 (da) Selvmordsmolekyle sammensætninger og fremgangsmåder
DK3638251T3 (da) Bisphosphocin gel formuleringer og brug deraf
DK3979827T3 (da) Næringssammensætning omfattende 2'fucosyllactose og 3'galactosyllactose
DK3710485T3 (da) Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder
DK4429686T3 (da) Postbiotiske sammensætninger omfattende b. longum cect- 7347 og l. rhamnosus cect- 8361 og terapeutiske anvendelser deraf
EP3744836A4 (en) Ketoreductase mutant and application thereof
DK3953348T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK4073346T3 (da) Borehulsværktøj og fremgangsmåder
DK3993777T3 (da) Komprimerede macitentansammensætninger, fremgangsmåder og anvendelser deraf
IL309079A (en) Methods and compositions
IL312965A (en) Immunogenic compositions and their uses
DK3712218T3 (da) Brandbeskyttelsessammensætning og anvendelse deraf
DK4103161T3 (da) Sammensætninger og anvendelser deraf
DK3718438T3 (da) Sofa-støttekonstruktion og sofa deraf
DK3617533T3 (da) Skrue og anvendelse deraf
DK3842052T3 (da) Sammensætning og fremgangsmåder til stabilisering af tarmfloraen og forbedring af hygiejnen
DK3622822T3 (da) Dominikia tenuihyphara-stamme, sammensætninger omfattende den og anvendelser heraf
EP4427636A4 (en) Chair
EP4429522A4 (en) RECLINING CHAIR ARRANGEMENT